Cetuximab biosimilar - Shanghai Henlius Biotech

Drug Profile

Cetuximab biosimilar - Shanghai Henlius Biotech

Alternative Names: Anti-EGFR monoclonal antibody 225 biosimilar - Shanghai Henlius Biotech; HLX 05

Latest Information Update: 18 Jun 2015

Price : $50

At a glance

  • Originator Shanghai Henlius Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 01 Dec 2014 Preclinical trials in Colorectal cancer in China (IV) before December 2014
  • 01 Dec 2014 Shanghai Henlius Biotech files an IND application with the CFDA in China for Colorectal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top